Therapy

KRM-1648 Useful in Intermittent TB Regimens

Published in TB and Outbreaks Week, July 22nd, 1996

The rifamycin KRM-1648 has potential for use in intermittent antituberculosis drug regimens, but the poor solubility of the drug may be a problem, according to a report from Denver, Colorado's National Jewish Center for Immunology and Respiratory Medicine.

The combined use of isoniazid, rifampin and pyrazinamide has made short-course antituberculosis chemotherapy possible.

"The discovery of long-lasting rifamycins created the possibility of intermittent drug regimens as has been shown in a number of observations with rifapentine, which accumulates to higher concentrations than does rifampin in macrophages," researcher Natan Mor and colleagues wrote...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1996-07-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry